Table 2.
Overall 1-year, 3-year, and 5-year observed survival (%) of patients with sinonasal cancer according to selected risk factors, Lombardy SNC registry, 2008–2020. Follow-up, 2008–2023.
| Variable | 1-Year (95% CI) | 3-Year (95% CI) | 5-Year (95% CI) |
|---|---|---|---|
| All patients | 77 (74–79) | 58 (54–61) | 49 (46–53) |
| Gender | |||
| Male | 77 (73–80) | 57 (53–61) | 49 (45–54) |
| Female | 76 (71–81) | 59 (53–64) | 49 (43–55) |
| Age | |||
| 0–49 | 85 (77–90) | 67 (57–74) | 59 (49–67) |
| 50–69 | 85 (81–89) | 69 (64–74) | 62 (57–67) |
| 70+ | 68 (63–72) | 46 (41–51) | 36 (31–41) |
| Period of diagnosis | |||
| 2008–2012 | 76 (71–81) | 58 (52–63) | 50 (44–55) |
| 2013–2016 | 77 (71–82) | 56 (50–62) | 47 (40–53) |
| 2017–2020 | 77 (72–82) | 59 (53–65) | 51 (45–57) |
| Cancer site (ICD-10 code) | |||
| Nasal cavity (C30.0) | 79 (72–83) | 64 (58–69) | 57 (51–62) |
| Paranasal sinuses (C31) | 75 (71–79) | 54 (50–58) | 44 (40–49) |
| Cancer morphology | |||
| Squamous cell carcinoma and variants | 79 (74–82) | 61 (56–66) | 53 (47–57) |
| Adenocarcinoma | 82 (77–86) | 65 (59–70) | 54 (48–59) |
| Neuroendocrine carcinoma | 73 (52–86) | 31 (15–49) | 27 (12–44) |
| Other epithelial neoplasm a | 63 (62–72) | 39 (29–49) | 37 (27–47) |
CI, confidence interval; ICD-10, International Classification of Diseases, Tenth Edition. a Sinonasal undifferentiated carcinoma (SNUC) and not-otherwise-specified (NOS) carcinoma.